104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. The experience of 5 reference dermatology units in Spain.

Pereyra-Rodriguez, Jose JuanDominguez-Cruz, JavierArmario-Hita, Jose CarlosRuiz-Villaverde, Ricardo2025-01-072025-01-072021-09-27https://hdl.handle.net/10668/25495enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Antibodies, Monoclonal, HumanizedDermatitis, AtopicDermatologyDouble-Blind MethodHumansSeverity of Illness IndexSpainTreatment Outcome104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. The experience of 5 reference dermatology units in Spain.research article34593266open access10.1016/j.abd.2020.08.0301806-4841PMC8790214https://doi.org/10.1016/j.abd.2020.08.030https://pmc.ncbi.nlm.nih.gov/articles/PMC8790214/pdf